HeyJaredThe Top Line
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development.
- Indexed episodes, last 90 days
- 19
- Latest publication
- Sep 18, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 10, 2026
Latest episodes
Inside the growing world of biopharma prediction markets (opens the original)
Read excerpt
Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. But they also create a new set of risks for an industry where employees, researchers, contractors and others may have access to confidential information that could give them an edge. In this episode of “The Top Line,” Fierce Biotech’s Will Maddox talks with David Oliwenstein, a partner at Pillsbury Winthrop Shaw Pittman and former SEC enforcement attorney, about how regulators ma
Clinical trials reach a new automation inflection point (Sponsored) (opens the original)
Read excerpt
Clinical development organizations are facing mounting pressure to do more with increasingly complex protocols, larger data sets and tighter timelines. While automation has improved individual processes, many of the industry's most persistent delays continue to occur between tasks, systems and teams. In this sponsored episode of The Top Line , host Lauren Ledger sits down with Greg Lever, director of AI and Technology Solutions at IQVIA, to discuss why agentic AI is gaining attention across clin
The future of RAS inhibitors (opens the original)
Read excerpt
Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach of RAS-targeting drugs. In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia sits down with Verastem Oncology CEO Dan Paterson and Chief Scientific Officer Jonathan Pachter, Ph.D., to discuss the significance of Revolution Medicines’ recent pancreatic cancer approval, Veraste
The people who stayed with the problem (opens the original)
Read excerpt
The 2026 Fierce 50 includes people and organizations working on very different problems across biopharma and healthcare, from designing new proteins and developing cancer medicines to protecting vaccine science, improving health literacy and expanding representation in medicine. In this episode of “The Top Line,” Fierce Editor-in-Chief Ayla Ellison looks at the stories behind several of this year’s honorees, including Revolution Medicines’ work targeting RAS, the protein-design research of David
Why Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored) (opens the original)
Read excerpt
The promise of precision medicine depends on more than scientific innovation. It also depends on whether eligible patients can be identified, tested and connected to the most appropriate treatment. In this episode of The Top Line , host Kelly Hogan is joined by Susanne Munksted, chief growth officer at Diaceutics, and Jordan Clark, chief customer officer, to discuss why many diagnostic-driven therapies still fail to reach their full potential. Drawing on findings from Diaceutics' practice gap st
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.